Pharmaceuticals & Therapeutics

A new poll shows two-thirds of workers are more likely to use GLP-1s with employer coverage, highlighting the role of cost, support, and stigma.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

Royal Biologics' new Fibrinet system uses a patient's own blood to create a living bandage, a major step forward for treating diabetic and venous ulcers.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Upsher-Smith launches its first prescription ear drop, a generic of Ciprodex®, entering a $118M market and promising a more affordable option for patients.

Apnimed has secured up to $150M to launch AD109, a potential first-ever pill for sleep apnea, promising relief for millions tired of CPAP machines.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

Preclinical data suggests an investigational drug can shift burn wounds from a state of chronic inflammation toward active regeneration and repair.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

A new $3M grant program targets the immune system's role in neurodegeneration, funding bold new research to combat Alzheimer's and Parkinson's.

The new pre-configured kits aim to reduce patient confusion and improve outcomes, tapping into the growing multi-billion dollar home healthcare market.

As Stryker preps its Q1 2026 report, all eyes are on whether the MedTech giant can sustain its momentum amid new products and industry-wide pressures.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

A 30-second 'Healthy Selfie' now detects metabolic risk. Backed by a $200K guarantee, this AI platform is set to redefine corporate wellness.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.